I
Irene Taylor
Researcher at Public Health England
Publications - 19
Citations - 790
Irene Taylor is an academic researcher from Public Health England. The author has contributed to research in topics: Virus & Ebola virus. The author has an hindex of 12, co-authored 19 publications receiving 522 citations. Previous affiliations of Irene Taylor include Health Protection Agency.
Papers
More filters
Journal ArticleDOI
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity.
Kathryn A. Ryan,Kevin R. Bewley,Susan A. Fotheringham,Gillian S. Slack,Phillip Brown,Yper Hall,Nadina Wand,Anthony C. Marriott,Breeze E. Cavell,Julia A. Tree,Lauren Allen,Marilyn Aram,Thomas Bean,Emily Brunt,Karen R. Buttigieg,Daniel P. Carter,Rebecca Cobb,Naomi Coombes,Steve J. Findlay-Wilson,Kerry J Godwin,Karen E. Gooch,Jade Gouriet,Rachel Halkerston,Debbie J Harris,Thomas Hender,Holly E. Humphries,Laura Hunter,Catherine M K Ho,Chelsea L Kennard,Stephanie Leung,Stephanie Longet,Didier Ngabo,Karen L. Osman,Jemma Paterson,Elizabeth J Penn,Steven T. Pullan,Emma Rayner,Oliver Skinner,Kimberley Steeds,Irene Taylor,Tom Tipton,Stephen Thomas,Carrie Turner,Robert J. Watson,Nathan R Wiblin,Sue Charlton,Bassam Hallis,Julian A. Hiscox,Simon G. P. Funnell,Mike Dennis,Catherine J. Whittaker,Michael G Catton,Julian Druce,Francisco J. Salguero,Miles W. Carroll,Miles W. Carroll +55 more
TL;DR: Characterise optimal infection dosage inducing upper respiratory tract (UTR) viral shedding, progression time of viral shed, and pathology in ferrets and finally provide evidence for protection after re-challenge in ferret model of SARS-CoV-2.
Journal ArticleDOI
Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model.
Stuart D. Dowall,Andrew Bosworth,Robert J. Watson,Kevin R. Bewley,Irene Taylor,Emma Rayner,Laura Hunter,Geoff Pearson,Linda Easterbrook,James Pitman,Roger Hewson,Miles W. Carroll +11 more
TL;DR: It is shown that replication of live EBOV is impaired by chloroquine in vitro, but no protective effects were observed in vivo when Ebola virus-infected guinea pigs were treated with chlorquine.
Journal ArticleDOI
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19.
Francisco J. Salguero,Andrew White,Gillian S. Slack,Susan A. Fotheringham,Kevin R. Bewley,Karen E. Gooch,Stephanie Longet,Holly E. Humphries,Robert J. Watson,Laura Hunter,Kathryn A. Ryan,Yper Hall,Laura Sibley,Charlotte Sarfas,Lauren Allen,Marilyn Aram,Emily Brunt,Phillip Brown,Karen R. Buttigieg,Breeze E. Cavell,Rebecca Cobb,Naomi Coombes,Alistair C. Darby,Owen Daykin-Pont,Michael J. Elmore,Isabel García-Dorival,Konstantinos Gkolfinos,Kerry J Godwin,Jade Gouriet,Rachel Halkerston,Debbie J Harris,Thomas Hender,Catherine M K Ho,Chelsea L Kennard,Daniel Knott,Stephanie Leung,Vanessa Lucas,Adam Mabbutt,Alexandra L. Morrison,Charlotte Nelson,Didier Ngabo,Jemma Paterson,Elizabeth J Penn,Steve Pullan,Irene Taylor,Tom Tipton,Stephen Thomas,Julia A. Tree,Carrie Turner,Edith Vamos,Nadina Wand,Nathan R Wiblin,Sue Charlton,Xiaofeng Dong,Bassam Hallis,Geoffrey Pearson,Emma Rayner,Andrew G. Nicholson,Simon G. P. Funnell,Julian A. Hiscox,Julian A. Hiscox,Mike Dennis,Fergus V. Gleeson,Sally Sharpe,Miles W. Carroll +64 more
TL;DR: It is shown that SARS-CoV-2 replicates in the upper and lower respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques, resembling the mild clinical cases of COVID-19 in humans.
Journal ArticleDOI
Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.
Graham J. Hatch,Victoria A. Graham,Kevin R. Bewley,Julia A. Tree,Mike Dennis,Irene Taylor,Simon G. P. Funnell,Simon R. Bate,Kimberley Steeds,Thomas Tipton,Thomas Bean,Laura Hudson,Deborah J. Atkinson,Gemma McLuckie,Melanie Charlwood,Allen D. G. Roberts,Julia Vipond +16 more
TL;DR: A monkeypox model of infection in cynomolgus macaques was used to evaluate two vaccines, Acam2000 and Imvamune, for protection against disease and found no significant difference between the levels of neutralizing antibody.
Journal ArticleDOI
Low Dose Influenza Virus Challenge in the Ferret Leads to Increased Virus Shedding and Greater Sensitivity to Oseltamivir
Anthony C. Marriott,Brian K. Dove,Catherine J. Whittaker,Christine B. Bruce,Kathryn A. Ryan,Thomas Bean,Emma Rayner,Geoff Pearson,Irene Taylor,Stuart D. Dowall,Jenna Plank,Edmund N. C. Newman,Wendy S. Barclay,Nigel J. Dimmock,Andrew J. Easton,Bassam Hallis,Nigel Silman,Miles W. Carroll +17 more
TL;DR: Low dose challenge gives a disease that more closely parallels the disease parameters of human influenza infection, and provides an improved pre-clinical model for the assessment of influenza therapeutics, and potentially, influenza vaccines.